Status:
COMPLETED
A Study of LY3084077 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy Volunteers
Eligibility:
All Genders
21-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3084077 in healthy participants. The study will also investigate how much of the study drug gets ...
Eligibility Criteria
Inclusion
- Have normal blood pressure
- Must be a healthy male or female who cannot become pregnant
- Have a body mass index (BMI) of 18.5 to 40.0 kg/m\^2, inclusive, at screening
Exclusion
- Have known allergies to fibroblast growth factor-21 (FGF21) analogues, glucagon-like peptide-1 (GLP1), GLP1-analogues or other related compounds
- Have previous exposure to FGF21 analogues or GLP1 analogues
- Have received live vaccine(s) within 1 month of screening, or intend to during the study
- Have previously completed or withdrawn from this study
- Have or used to have health problems or laboratory test results or electrocardiogram (ECG) readings that in the opinion of the doctor, could make it unsafe to participate, or interfere with understanding the results of the study
- Have received treatment with biologic agents (such as monoclonal antibodies) within 3 months or 5 half-lives (whichever is longer) prior to dosing
- Have problems with the immune system, due to a disease or treatment
- Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2
- Have a history of pancreatitis
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT01846702
Start Date
May 1 2013
End Date
December 1 2013
Last Update
July 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Singapore, Singapore, 117597